N@N

50.14% Of All NASDAQ Trading Thursday Was Short Selling. TIXC, NXXI, ALVR, PLCM, THRX, EPCT Highest % Of Daily Trading Volume

^{Published on 2009-09-18 09:30:35, Last Modified on 2010-12-22 14:45:11 - WOPRAI}
 

September 18, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, has reviewed the NASDAQ Daily Short Volume Report for Thursday, September 17th, 2009 and come to the following statistical conclusions. There were 6,809 stocks with daily short volume reported and total NASDAQ trading volume of 2,030,223,148 shares. Total Daily Short Volume was 1,018,045,603 shares. 50.14% of all trading on the NASDAQ Thursday was short selling. The chart below highlights 6 stocks that had unusually high percentages of their total daily trading volume attributed to short sales. Tix Corp (NASDAQ: TIXC), Nutrition 21 (NASDAQ: NXXI), Alvarion (NASDAQ: ALVR), Polycom (NASDAQ: PLCM), Theravance (NASDAQ: THRX) and EpiCept (NASDAQ: EPCT). To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

DATE SYMBOL SHORT VOLUME TOTAL VOLUME MARKET PERCENT

20090917 TIXC 53,800 56,900 Q 94.55%

20090917 NXXI 336,544 380,464 Q 88.46%

20090917 ALVR 125,105 158,540 Q 78.91%

20090917 PLCM 481,156 627,385 Q 76.69%

20090917 THRX 79,846 107,785 Q 74.08%

20090917 EPCT 100,553 136,213 Q 73.82%

In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesai naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.

Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.

The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.

Tix Corporation (NASDAQ: TIXC), an integrated entertainment company, focuses on ticketing services, event merchandising, and the production and promotion of live entertainment in the United States. The company operates in three segments: Ticket Services, Event and Branded Merchandising, and Live Entertainment. The Ticket Services segment provides ticketing services, including sale discount and premium tickets; offers group sale services; and sells premium tickets for sporting events, concerts, tours, and theatres. The Exhibit and Event Merchandising segment provides exhibit and event merchandising, such as the provision of retail specialty stores with branded merchandise for touring museum exhibitions and theatrical productions, and the ownership and operation of retail stores with custom-branded products for sale. The Live Entertainment segment operates as a live entertainment presenter, and produces and presents live theater and concerts. This segment books touring theatrical and concert presentations, as well as participates in the development and roll out of theatrical and concert presentations originating on Broadway in New York or the West end in London. It also invests in shows or productions in advance of their initial tours to obtain presentation and merchandising rights. This segment sells tickets to these programs through subscriber-based businesses and sales teams, as well as through print, radio, television, outdoor, and Internet-mediated marketing tools. The company was formerly known as Cinema Ride, Inc. and changed its name to Tix Corporation in March 2005. Tix Corporation was founded in 1993 and is headquartered in Studio City, California.

Nutrition 21, Inc. (NASDAQ: NXXI), a nutritional bioscience company, develops, markets, and distributes clinically substantiated nutritional supplements in the United States. The company sells Chromax branded chromium picolinate to vitamin and supplement manufacturers and marketers, as well as directly to retailers for use in human and animal nutrition products. It also commercializes Diabetes Essentials as a nutritional complement to medical treatment for people with type 2 diabetes. In addition, the company offers a line of Omega-3 products, including Maximum Strength Omega-3 and Joint Relief Advanced Formula for promoting cardiovascular and joint health. It offers its products through direct response channels, including TV infomercials, radio, print, direct mail, and Internet e-commerce, as well as through retail distribution channel. In addition, Nutrition 21, Inc. grants patent licenses to manufacturers of vitamin and mineral supplements. The company, formerly known as Applied Microbiology, Inc., was founded in 1983 and is headquartered in Purchase, New York.

Alvarion Ltd. (NASDAQ: ALVR) supplies top-tier carriers, Internet service providers (ISPs), and private network operators with solutions based on the Worldwide Interoperability for Microwave Access (WiMAX) standard, as well as other wireless broadband solutions. The company provides WiMAX and non-WiMAX wireless broadband systems, and launched 250 commercial WiMAX deployments worldwide. Its solutions are designed to cover a range of frequency bands with fixed, portable, and mobile applications to enable the delivery of personal broadband services, business and residential broadband access, corporate virtual private network (VPN), toll quality telephony, mobile base station feeding, hotspot coverage extension, and services for various vertical markets, such as municipalities, public safety, mining, oil and gas, utilities, video surveillance, and border control. The companyais business mainly focuses on solutions, based on the WiMAX standard, that are used for primary wireless broadband access. In addition, Alvarion continues to sell its non-WiMAX products. Its solutions provide high-speed wireless alast mileai connection to the Internet for homes and businesses in both developed and emerging markets. The company was formerly known as BreezeCOM Ltd. and changed its name to Alvarion Ltd. as result of merger with Floware Wireless Systems Ltd. in August 2001. Alvarion Ltd. was founded in 1992 and is headquartered in Tel Aviv, Israel.

Polycom, Inc. (NASDAQ: PLCM) provides communications solutions to enterprise and public sector customers to enable voice, video, and content communications. It operates in three segments: Video Solutions, Voice Communications Solutions, and Services. The Video Solutions segment offers video communications products, including telepresence, room, desktop, and personal video products; and infrastructure products, such as video and voice media servers, network management, security, streaming, and recording solutions for meeting rooms, conference rooms, training rooms, courtrooms, classrooms, offices, boardrooms, auditoriums, and permanent installations. The Voice Communications Solutions segment offers conference phone, wired desktop voice products, and wireless handset voice products. The Services segment offers integration services, including consulting, education, design, and project management; consulting services, such as planning and needs analysis; design services, including room design and custom solutions; and project management, installation, and training services. This segment also offers maintenance services, including telephone support, software upgrades and updates, parts exchange, on-site assistance, and direct access; and professional services solutions, such as assessments, implementation, network consulting, wireless services application integration, and advanced project management services. The company sells its products through a network of channel partners, including distributors, value-added resellers, systems integrators, communications service providers, and retailers primarily in North America, Europe, the Middle East, Africa, Asia, Caribbean, and Latin America. Polycom has strategic relationships with Avaya, Cisco, and Nortel to develop and market voice-over-Internet protocol and video communications solutions. The company was founded in 1990 and is headquartered in Pleasanton, California.

Theravance, Inc. (NASDAQ: THRX), a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines across various therapeutic areas, including respiratory disease, bacterial infections, and gastrointestinal motility dysfunction. It offers Telavancin (cSSSI), a bactericidal injectable antibiotic for the treatment of complicated skin and skin structure infections; Telavancin (HAP) that is used to treat hospital-acquired pneumonia or nosocomial pneumonia; and Horizon to develop and commercialize long-acting beta2 agonist (LABA) product candidate as a single agent new medicine for the treatment of chronic obstructive pulmonary disease (COPD) and as part of a new combination medicine with an inhaled corticosteroid (ICS) for the treatment of asthma and/or a long acting muscarinic antagonist (LAMA) for COPD. In addition, it offers GSK961081, a bifunctional muscarinic antagonist-beta2 agonist compound, which is in phase 2 clinical studies; and TD-5108, a gastrointestinal motility dysfunction program for the treatment of chronic constipation and other disorders related to reduced gastrointestinal motility. The company has collaboration arrangements with Astellas Pharma, Inc. for the development and commercialization of Telavancin; GlaxoSmithKline plc to develop and commercialize LABA product candidates; and AstraZeneca AB to develop and commercialize intravenous anesthetic compounds. The company also has a strategic alliance with GlaxoSmithKline plc. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance was founded in 1996 and is headquartered in South San Francisco, California.

EpiCept Corporation (NASDAQ: EPCT), a specialty pharmaceutical company, focuses on the development of pharmaceutical products for the treatment of cancer and pain in the United States and Germany. The companyais lead oncology product candidate is Ceplene, which is used for the treatment of acute myeloid leukemia. Its cancer product portfolio includes Azixa, a Phase II clinical trial product to treat the patients with primary glioblastoma and melanoma that has metastasized to the brain and non-small-cell lung cancer that has spread to the brain; and Crinobulin (EPC2407), a Phase I clinical trial completed oncology product candidate for the treatment of patients with advanced solid tumors and lymphomas. The companyais pain product portfolio comprises EpiCept NP-1, a Phase II clinical trial product, which is a prescription topical analgesic cream for the relief of peripheral neuropathies; LidoPAIN BP, a prescription analgesic non-sterile patch to provide sustained topical delivery of lidocaine for the treatment of acute or recurrent lower back pain; EpiCept MP/DP, a spray gel matrix of morphine and lidocaine for the treatment of oral mucositis and dental pain; LidoPAIN TV, a topical lidocaine patch applied to the periauricular skin region (behind the ear) for the treatment of tinnitus; and LidoPAIN HM, a topical lidocaine patch applied to the forehead for the treatment of headaches. It principally has strategic alliances with Myriad Genetics, Inc. and DURECT Corporation. The company was founded in 1993 and is based in Tarrytown, New York.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each monthais short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies or third parties pay $995 per month to purchase data for information provided in monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net